The Pharma Data

APRIL 7, 2021

months with chemotherapy (HR: 0.43; 95% CI: 0.35-0.54; months (HR: 0.51; 95% CI: 0.41-0.62; Trodelvy is directed to the Trop-2 receptor, a protein frequently expressed in multiple types of epithelial tumors, including TNBC, where high expression is associated with poor survival and relapse. months from 1.7 0.54; p<0.0001).

HR 52

HR Genotype FDA Approval Genotoxicity 52

The Pharma Data

NOVEMBER 24, 2020

Results from the ILLUMINATE-A and ILLUMINATE-B studies demonstrate that Oxlumo addresses the underlying pathophysiology of PH1 in adults, children and infants, and we believe this newly approved medicine has the potential to change the course of this progressive disease,” said Akshay Vaishnaw, M.D., 0.514 mmol/24 hr/1.73

FDA Approval 52

FDA Approval Production RNA Medicine 52

The Pharma Data

APRIL 14, 2021

Tagawa, MD, MS, FACP, Professor of Medicine and Urology at Weill Cornell Medicine, an oncologist at New York-Presbyterian/Weill Cornell Medical Center and principal investigator of the TROPHY study. Canada, Switzerland and Australia, as well as in Singapore through our partner Everest Medicines. About Trodelvy.

Genotype 52

Genotype Containment FDA Approval Genotoxicity 52